{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:06:39Z","timestamp":1776834399697,"version":"3.51.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>AL amyloidosis is a rare plasma cell disorder that causes progressive organ dysfunction due to extracellular deposition of misfolded immunoglobulin light chains. Reports from Central Asia are scarce, and there is limited documentation of successful integration of daratumumab-based therapy with autologous hematopoietic stem cell transplantation (auto-HSCT) in this region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 65-year-old woman presented with progressive left supraclavicular lymphadenopathy. Examination revealed bilateral cervical and supraclavicular lymphadenopathy with an ECOG performance status of 1. Laboratory testing showed elevated \u03ba free light chains (50.96 mg\/L; \u03ba\/\u03bb ratio 12.0). Lymph node biopsy with Congo red staining revealed amyloid deposits with apple-green birefringence, and immunohistochemical protein typing confirmed AL amyloidosis type kappa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions and outcomes<\/jats:title>\n                    <jats:p>The patient received four cycles of bortezomib\u2013cyclophosphamide\u2013dexamethasone without hematologic response, followed by two cycles of daratumumab\u2013cyclophosphamide\u2013bortezomib\u2013dexamethasone, achieving a very good partial response (dFLC reduced from 46.7 to 11.9 mg\/L) and renal recovery (GFR from 21 to 71 mL\/min). She underwent high-dose melphalan conditioning and auto-HSCT, with neutrophil engraftment on day +19 and grade 3 mucositis as the main complication. At one-year follow-up, she remains in hematologic and organ remission on monthly daratumumab maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case was selected for reporting due to several distinctive clinical and organizational aspects. AL amyloidosis remains underdiagnosed in Central Asia, and experience with daratumumab-based regimens combined with autologous hematopoietic stem cell transplantation (auto-HSCT) is limited in this region. At our center, patients with suspected plasma cell dyscrasias frequently present with advanced or atypical disease manifestations, often leading to diagnostic delays. Compared with other AL amyloidosis cases treated at our institution, this patient demonstrated an uncommon presentation dominated by extensive extramedullary lymph node involvement, absence of overt cardiac manifestations, and prolonged diagnostic latency. Furthermore, the case illustrates the feasibility of integrating modern induction therapy with daratumumab, successful stem cell mobilization, and auto-HSCT in a resource-variable healthcare setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1685050","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:31:12Z","timestamp":1776832272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Autologous stem cell transplantation in a patient diagnosed with AL amyloidosis in Kazakhstan"],"prefix":"10.3389","volume":"16","author":[{"given":"Olga","family":"Kolesnikova","sequence":"first","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Kemaykin","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhandos","family":"Burkitbayev","sequence":"additional","affiliation":[{"name":"Chairman of the Board, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azat","family":"Karabekov","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandr","family":"Kolesnev","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayagul","family":"Ainabay","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vildanova","family":"Ruzal","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiramgul","family":"Yusupova","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariza","family":"Shokubaeva","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbota","family":"Tursyn","sequence":"additional","affiliation":[{"name":"Center for Oncohematology and Bone Marrow Transplantation, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuldyz","family":"Kuanysh","sequence":"additional","affiliation":[{"name":"Department of Scientific Management, National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002762","article-title":"Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis","volume":"135","author":"Basset","year":"2020","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1070","article-title":"Light chain amyloidosis: epidemiology, staging, and prognostication","volume":"18","author":"Baker","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.004","article-title":"Primary amyloidosis with renal involvement: outcomes in 77 consecutive patients at a single center","volume":"17","author":"Wong","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008737","article-title":"How I treat AL amyloidosis","volume":"139","author":"Palladini","year":"2022","journal-title":"Blood"},{"key":"B7","article-title":"NCCN clinical practice guidelines in oncology: systemic light chain amyloidosis. Version 1.2025","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251411783","article-title":"Hematopoietic stem cell transplantation for multiple myeloma in Kazakhstan: Ten-year single-center experience","volume":"54","author":"Kemaykin","year":"2026","journal-title":"J Int Med Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.06.021","article-title":"Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy","volume":"17","author":"Wood","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.2023101","article-title":"AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management","volume":"52","author":"Tan","year":"2023","journal-title":"Ann Acad Med Singap"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro\u2013brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro\u2013brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem cell transplantation for light chain amyloidosis: decreased early mortality over time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3000605251326804","DOI":"10.1177\/03000605251326804","article-title":"Case study: acute plasmoblastic leukemia presentation following effective haploidentical hematopoietic stem cell transplantation therapy","volume":"53","author":"Karabekov","year":"2025","journal-title":"J Int Med Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007826","article-title":"Phase 1\/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis","volume":"6","author":"Rosenbaum","year":"2022","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023194","article-title":"Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement","volume":"58","author":"Jang","year":"2023","journal-title":"Blood Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3109\u201313","DOI":"10.3324\/haematol.2025.287664","article-title":"A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed\/refractory systemic AL amyloidosis","volume":"110","author":"Vohra","year":"2025","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756528","article-title":"Phase 2 trial of pomalidomide and dexamethasone as salvage treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40164-021-00236-z","article-title":"Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications","volume":"10","author":"Xu","year":"2021","journal-title":"Acta Pharmacol Sin B"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4947","article-title":"The t(11;14) translocation is associated with poor outcome in patients with newly diagnosed AL amyloidosis treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomized, double-blind, multicentre, phase 3 study","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/S2152-2650(21)02156-X","article-title":"Survival benefit observed with birtamimab in Mayo Stage IV AL amyloidosis supports initiation of confirmatory AFFIRM-AL phase 3 study","volume":"21","author":"Gertz","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1685050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:31:30Z","timestamp":1776832290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1685050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1685050"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1685050","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1685050"}}